A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer

Kai Zhang, Phillip D. Stricker, Martin Löhr, Michael K. Stehling, M Suberville, Olivier Cussenot, Luca Lunelli, Chi‐Fai Ng, Jeremy Yuen‐Chun Teoh, Pilar Laguna, Jean de la RosetteProstate 2024 · DOI

Abstract: For men with localized prostate cancer, Irreversible Electroporation (IRE) could achieve good urinary and sexual function outcomes and a reasonable oncological result. The real-world data are consistent with earlier studies, including recently published randomized controlled studies. The long-term oncological results need further investigation and follow-up.

Introduction: The Challenge of Localized Prostate Cancer

The current standard of care for localized prostate cancer typically involves radical prostatectomy or radiation therapy. While effective at eradicating cancer, these whole-gland treatments often result in significant side effects, such as urinary incontinence and erectile dysfunction, due to collateral damage to surrounding nerves and blood vessels.

Focal therapy aims to treat only the tumor, sparing healthy tissue. However, traditional thermal methods like cryotherapy or high-intensity focused ultrasound (HIFU) can still cause damage to the prostate's structural "scaffolding." This study investigates Irreversible Electroporation (IRE), a non-thermal ablation technique, as a potential solution to preserve function while maintaining oncological control.

Study Population and Methodology

This prospective, multi-center international study tracked 411 patients with histologically confirmed prostate cancer between 2015 and 2020. The primary technology used was the NanoKnife™ system, which delivers high-voltage, low-energy direct current pulses. Unlike thermal methods, IRE creates permanent nanopores in cell membranes, triggering programmed cell death (apoptosis) without generating heat that would damage nearby connective tissues or nerves.

Baseline characteristics of the 411-patient IRE cohort, including age, prostate volume, and initial functional scores.

Patients were followed for a median of 24 months. Functional outcomes were assessed using the International Prostate Symptom Score (IPSS) for urinary health and the International Index of Erectile Function (IIEF-5) for sexual health. Safety was monitored via the CTCAE scale, and oncological success was evaluated through follow-up biopsies at 12–18 months.

Key Results and Insights

Functional Preservation and Safety

One of the most significant findings was the high safety profile of IRE. Major adverse events (Grade 3 or higher) were extremely rare, and treatment-related events dropped below 1% after the six-month mark.

Functional recovery followed a distinct "V-shaped" pattern. Urinary symptoms (IPSS) initially worsened at three months post-procedure but improved to better-than-baseline levels by six months. Sexual health scores (IIEF-5) showed a manageable impact, dropping from 16.0 at baseline to 12.1 at three months and remaining stable thereafter, a significantly better outcome than typically seen with radical surgery.

Biochemical markers provided a strong signal of successful ablation. PSA levels showed a dramatic reduction of 96.2% from their post-operative peak within the first three months.

PSA levels (ng/ml) over 60 months, showing the characteristic post-procedure spike followed by a sustained reduction.

In the subset of patients who underwent follow-up biopsies (n=116), 24.1% were found to have clinically significant prostate cancer (Gleason score ≥ 3+4). While not a total cure, these results are consistent with other focal therapy outcomes and highlight IRE's role as a middle-ground treatment between active surveillance and radical intervention.

Limitations and Future Directions

While promising, the study notes several areas for further research:

  1. Biopsy Compliance: Only 28% of the total cohort underwent the recommended 1-year follow-up biopsy, which may affect the reported oncological failure rates.
  2. Long-term Data: Prostate cancer is slow-growing; while 24-month data is encouraging, 5-to-10-year follow-ups are necessary to fully compare IRE to radical treatments.
  3. Imaging Integration: Interpreting post-treatment MRIs remains challenging. Future work should explore the use of artificial intelligence and radiomics to identify residual cancer more accurately without relying solely on invasive biopsies.

In conclusion, IRE represents a robust "middle ground" for localized prostate cancer, successfully threading the needle between the side effects of surgery and the risks of surveillance.

Summary updated

Abstract

For men with localized prostate cancer, IRE could achieve good urinary and sexual function outcomes and a reasonable oncological result. The real-world data are consistent with earlier studies, including recently published randomized controlled studies. The long-term oncological results need further investigation and follow-up.
BibTeX
@inproceedings{zhang2024multi,
  author = {Kai Zhang and Phillip D. Stricker and Martin Löhr and Michael K. Stehling and M Suberville and Olivier Cussenot and Luca Lunelli and Chi‐Fai Ng and Jeremy Yuen‐Chun Teoh and Pilar Laguna and Jean de la Rosette},
  title = {{A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer}},
  booktitle = {Prostate},
  year = {2024},
  doi = {10.1038/s41391-023-00783-y},
}
Figure